Advertisement

Topics

Artielle ImmunoTherapeutics Company Profile

19:00 EDT 24th September 2017 | BioPortfolio


News Articles [58 Associated News Articles listed on BioPortfolio]

Selexis and OSE Immunotherapeutics to support OSE-127 (Effi-7) development

Swiss-based Selexis has signed a commercial licence agreement to provide French biotechnology firm OSE Immunotherapeutics with access to high-performance research cell banks (RCBs) from its SUREtechno...

OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi in Advanced Lung Cancer

Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) today announced that following the recommendation by IDMC (independent experts) on the phase 3 clinical stud...

OSE Immunotherapeutics Receives €9.2 Million Grant From Bpifrance "Invest in the Future Program" for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)

Regulatory News: This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170719005529/en/ OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR00...

OSE Temporarily Halts Patient Enrollment in Phase 3 Lung Cancer Study

NewsOSE Immunotherapeutics announces temporary pause of patient accrual while continuing treatment for patients already enrolled in Phase 3 clinical trial of Tedopi in advanced lung cancer.

OSE Immunotherapeutics Presents New Data on Anti-SIRPa (Effi-DEM), the Checkpoint Inhibitor blocking Pro-Tumor and Suppressor Myeloid Cells at "Advances in Immuno-Oncology Congress", London, May 15-16, 2017

Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) announced today that the Company presented in oral session significant data on Selective Anti-SIRPa OSE-172 ...

OSE Immunotherapeutics halts recruitment in cancer vaccine trial

OSE Immunotherapeutics SA has halted recruitment in a Phase III trial of its cancer vaccine Tedopi (OSE2101). 

Feinstein, Karolinska license rights to start-up Applied Immunotherapeutics

The Feinstein Institute for Medical Research and Karolinska Institute granted Applied Immunotherapeutics Inc. (start-up developing treatments for autoimmune and inflammatory diseases) rights to discov...

French Biotech Enters New Agreement to Advance its IBD Immunotherapy

OSE Immunotherapeutics has teamed up with Selexis in a new license agreement to support the development of its IL-7 antagonist for the treatment of IBD. In the end of last year, French OSE Immunothera...

Drugs and Medications [0 Results]

None

PubMed Articles [119 Associated PubMed Articles listed on BioPortfolio]

Immunotherapy is Different: Implications for Immunotherapy Clinical Trial Design.

Cancer Immunotherapetics differ fundamentally from most cancer therapies in that they involve manipulation of the immune system to induce an anti-tumor response. This fundamental difference results in...

Human Vaccines & Immunotherapeutics awards Top Reviewer of the Year.

Human Vaccines & Immunotherapeutics: News.

Human Vaccines & Immunotherapeutics: News.

Human Vaccines & Immunotherapeutics: News.

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [22 Associated Companies listed on BioPortfolio]

Artielle ImmunoTherapeutics

Innate Immunotherapeutics Limited

Innate Immunotherapeutics Limited is a public unlisted biopharmaceutical company based in Auckland, New Zealand. The company is focused on the development of a new generation of i...

Selexis SA and OSE Immunotherapeutics SA

Our ambition is to become a world leader in activation and regulation immunotherapies: OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focus...

OSE Immunotherapeutics

Avant Immunotherapeutics

AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company is developing a...

More Information about "Artielle ImmunoTherapeutics" on BioPortfolio

We have published hundreds of Artielle ImmunoTherapeutics news stories on BioPortfolio along with dozens of Artielle ImmunoTherapeutics Clinical Trials and PubMed Articles about Artielle ImmunoTherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Artielle ImmunoTherapeutics Companies in our database. You can also find out about relevant Artielle ImmunoTherapeutics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record